Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.

Jin Sook Yoon, Jae Chan Kim, Sang Yeul Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

PURPOSE: To compare the efficacies and safeties of Meditoxin (Medy-Tox, Korea) and Botox in the treatment of essential blepharospasm. METHODS: We performed a double-blind, randomized, comparative trial comparing Meditoxin and Botox for treatment of blepharospasm in 60 patients from the intention-to-treat (ITT) population and 52 patients from the per-protocol (PP) population. We analyzed the improvements in severity of spasm (SS) at four weeks post-injection as a primary efficacy outcome. Changes in eyelid closing force (CF) and functional visual status (FVS) after injection were analyzed for secondary efficacy outcomes, and adverse effects were demonstrated for the safety evaluation. RESULTS: Improvement in SS was noted in 90.3% of the Meditoxin group and 86.2% of the Botox group. There were no significant differences between treatment groups in the changes of CF and FVS post-injection (p>0.05). Since the lower limit of the 95% confidence interval (-1.76% for ITT, -1.64% for PP) was over the -15% threshold, we determined that Meditoxin was not inferior to Botox in either the ITT or PP populations. Adverse effects developed in 16.1% of the Meditoxin group and 27.6% of the Botox group, but no serious adverse events were found in either group. CONCLUSIONS: Meditoxin and Botox were comparable in efficacy and safety in the treatment of essential blepharospasm.

Original languageEnglish
Pages (from-to)137-141
Number of pages5
JournalKorean journal of ophthalmology : KJO
Volume23
Issue number3
DOIs
Publication statusPublished - 2009 Sep

Fingerprint

Type A Botulinum Toxins
Spasm
Safety
Injections
Therapeutics
Blepharospasm
Population
Eyelids
Korea
Benign essential blepharospasm
onabotulinumtoxinA
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{0e53cf3b653e490d8040f9b44cc8b307,
title = "Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.",
abstract = "PURPOSE: To compare the efficacies and safeties of Meditoxin (Medy-Tox, Korea) and Botox in the treatment of essential blepharospasm. METHODS: We performed a double-blind, randomized, comparative trial comparing Meditoxin and Botox for treatment of blepharospasm in 60 patients from the intention-to-treat (ITT) population and 52 patients from the per-protocol (PP) population. We analyzed the improvements in severity of spasm (SS) at four weeks post-injection as a primary efficacy outcome. Changes in eyelid closing force (CF) and functional visual status (FVS) after injection were analyzed for secondary efficacy outcomes, and adverse effects were demonstrated for the safety evaluation. RESULTS: Improvement in SS was noted in 90.3{\%} of the Meditoxin group and 86.2{\%} of the Botox group. There were no significant differences between treatment groups in the changes of CF and FVS post-injection (p>0.05). Since the lower limit of the 95{\%} confidence interval (-1.76{\%} for ITT, -1.64{\%} for PP) was over the -15{\%} threshold, we determined that Meditoxin was not inferior to Botox in either the ITT or PP populations. Adverse effects developed in 16.1{\%} of the Meditoxin group and 27.6{\%} of the Botox group, but no serious adverse events were found in either group. CONCLUSIONS: Meditoxin and Botox were comparable in efficacy and safety in the treatment of essential blepharospasm.",
author = "Yoon, {Jin Sook} and Kim, {Jae Chan} and Lee, {Sang Yeul}",
year = "2009",
month = "9",
doi = "10.3341/kjo.2009.23.3.137",
language = "English",
volume = "23",
pages = "137--141",
journal = "Korean journal of ophthalmology : KJO",
issn = "1011-8942",
publisher = "Seoul Kjo",
number = "3",

}

Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. / Yoon, Jin Sook; Kim, Jae Chan; Lee, Sang Yeul.

In: Korean journal of ophthalmology : KJO, Vol. 23, No. 3, 09.2009, p. 137-141.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.

AU - Yoon, Jin Sook

AU - Kim, Jae Chan

AU - Lee, Sang Yeul

PY - 2009/9

Y1 - 2009/9

N2 - PURPOSE: To compare the efficacies and safeties of Meditoxin (Medy-Tox, Korea) and Botox in the treatment of essential blepharospasm. METHODS: We performed a double-blind, randomized, comparative trial comparing Meditoxin and Botox for treatment of blepharospasm in 60 patients from the intention-to-treat (ITT) population and 52 patients from the per-protocol (PP) population. We analyzed the improvements in severity of spasm (SS) at four weeks post-injection as a primary efficacy outcome. Changes in eyelid closing force (CF) and functional visual status (FVS) after injection were analyzed for secondary efficacy outcomes, and adverse effects were demonstrated for the safety evaluation. RESULTS: Improvement in SS was noted in 90.3% of the Meditoxin group and 86.2% of the Botox group. There were no significant differences between treatment groups in the changes of CF and FVS post-injection (p>0.05). Since the lower limit of the 95% confidence interval (-1.76% for ITT, -1.64% for PP) was over the -15% threshold, we determined that Meditoxin was not inferior to Botox in either the ITT or PP populations. Adverse effects developed in 16.1% of the Meditoxin group and 27.6% of the Botox group, but no serious adverse events were found in either group. CONCLUSIONS: Meditoxin and Botox were comparable in efficacy and safety in the treatment of essential blepharospasm.

AB - PURPOSE: To compare the efficacies and safeties of Meditoxin (Medy-Tox, Korea) and Botox in the treatment of essential blepharospasm. METHODS: We performed a double-blind, randomized, comparative trial comparing Meditoxin and Botox for treatment of blepharospasm in 60 patients from the intention-to-treat (ITT) population and 52 patients from the per-protocol (PP) population. We analyzed the improvements in severity of spasm (SS) at four weeks post-injection as a primary efficacy outcome. Changes in eyelid closing force (CF) and functional visual status (FVS) after injection were analyzed for secondary efficacy outcomes, and adverse effects were demonstrated for the safety evaluation. RESULTS: Improvement in SS was noted in 90.3% of the Meditoxin group and 86.2% of the Botox group. There were no significant differences between treatment groups in the changes of CF and FVS post-injection (p>0.05). Since the lower limit of the 95% confidence interval (-1.76% for ITT, -1.64% for PP) was over the -15% threshold, we determined that Meditoxin was not inferior to Botox in either the ITT or PP populations. Adverse effects developed in 16.1% of the Meditoxin group and 27.6% of the Botox group, but no serious adverse events were found in either group. CONCLUSIONS: Meditoxin and Botox were comparable in efficacy and safety in the treatment of essential blepharospasm.

UR - http://www.scopus.com/inward/record.url?scp=73349090586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349090586&partnerID=8YFLogxK

U2 - 10.3341/kjo.2009.23.3.137

DO - 10.3341/kjo.2009.23.3.137

M3 - Article

C2 - 19794937

AN - SCOPUS:73349090586

VL - 23

SP - 137

EP - 141

JO - Korean journal of ophthalmology : KJO

JF - Korean journal of ophthalmology : KJO

SN - 1011-8942

IS - 3

ER -